Suchergebnisse - "Goadsby, Peter"

PubPharm (29)

1

Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed : LIBERTY 3-Year Study

enthalten in: Neurology | 2024

von Reuter, U. | Goadsby, P. | Ferrari, M. | +9

2

Ubrogepant for the treatment of migraine attacks during the prodrome : a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA

enthalten in: Lancet (London, England) | 2023

von Dodick, D. | Goadsby, P. | Schwedt, T. | +7

3

Atogepant for the preventive treatment of chronic migraine (PROGRESS) : a randomised, double-blind, placebo-controlled, phase 3 trial

enthalten in: Lancet (London, England) | 2023

von Pozo-Rosich, P. | Ailani, J. | Ashina, M. | +14

CommentIn: Lancet. 2023 Sep 2;402(10404):748-749. - PMID 37516124

4

Estimating treatment effects on health utility scores for patients living with migraine : a post hoc analysis of the DELIVER trial

enthalten in: Expert review of pharmacoeconomics & outcomes research | 2023

von Jönsson, L. | Regnier, S. | Kymes, S. | +4

5

Eptinezumab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures

enthalten in: European journal of neurology | 2023

von Goadsby, P. | Barbanti, P. | Lambru, G. | +5

6

Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA : a phase 3, double-blind, randomised, placebo-controlled multicentre trial

enthalten in: The Lancet. Neurology | 2023

von Lipton, R. | Croop, R. | Stock, D. | +6

CommentIn: Lancet Neurol. 2023 Mar;22(3):190-191. - PMID 36804077

7

Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study

enthalten in: The journal of headache and pain | 2022

von Barbanti, P. | Goadsby, P. | Lambru, G. | +5

8

Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention

enthalten in: Headache | 2022

von Lipton, R. | Goadsby, P. | Dodick, D. | +9

9

Atogepant for the Preventive Treatment of Migraine

enthalten in: The New England journal of medicine | 2021

von Ailani, J. | Lipton, R. | Goadsby, P. | +106

10

Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2-4 preventives were not useful : results from the LIBERTY study

enthalten in: Journal of neurology, neurosurgery, and psychiatry | 2021

von Lanteri-Minet, M. | Goadsby, P. | Reuter, U. | +4